Jan 04, 2021 / 01:30PM GMT
Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Atara Biotherapeutics Conference Call. (Operator Instructions)
I'd now like to hand the conference over to your host today, Mr. Eric Hyllengren, Vice President, Investor Relations and Finance. Please go ahead, sir.
Eric Hyllengren - Atara Biotherapeutics, Inc. - Head of IR & Finance
Thank you, operator. Good morning, everyone, and welcome to the Atara Biotherapeutics Conference Call. On today's call, members from the Atara executive team will provide an update on our tab-cel regulatory progress. This morning, we issued a press release providing a regulatory update for tab-cel in EBV-positive PTLD. This press release is available in the Investor and Media section at atarabio.com.
Joining me on today's call are Dr. Pascal Touchon, President and Chief Executive Officer; Dr. Jakob Dupont, Executive Vice President and Global Head of Research and Development; Dr. AJ Joshi, Chief Medical Officer; Joe Newell, Chief Operations Officer; and Utpal Koppikar, Chief Financial Officer.
Atara Biotherapeutics Inc Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Transcript
Feb 06, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers